Cancer News and Research

Latest Cancer News and Research

New article finds no compelling evidence for withdrawing nitrous oxide from operating theaters

A debate at this year's Euroanaesthesia meeting in Berlin will focus on whether laughing gas (nitrous oxide) should be banned from the operating room.

1 Jun 2015

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Mirati Therapeutics, Inc. today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2015.

1 Jun 2015

PGDx introduces ImmunoSelect-R service to support development of immuno-oncology cancer therapies

Personal Genome Diagnostics, Inc., a provider of advanced cancer genome analysis and testing services, today announced the launch of its ImmunoSelect-R service designed to identify mutant neoantigens and support development of immuno-oncology cancer therapies.

1 Jun 2015

Study: Removing more tissue during partial mastectomy could reduce need for second surgery

Removing more tissue during a partial mastectomy could spare thousands of breast cancer patients a second surgery, according to a Yale Cancer Center study. The findings were published online May 30 in the New England Journal of Medicine and presented at the 2015 Annual Meeting of the American Society of Clinical Oncology in Chicago.

1 Jun 2015

CHEMOSAT treatment of UM patients with hepatic metastases highlighted at ASCO 2015

Delcath Systems, Inc., a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that results of a large, European single-center experience of the treatment of uveal melanoma patients with hepatic metastases with the Delcath Hepatic CHEMOSAT® Delivery System, were highlighted in an on-line abstract at the American Society of Clinical Oncology Annual Meeting 2015.

1 Jun 2015

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the presentation of data from three studies that demonstrate the utility of Caris Molecular Intelligence®, the company's panomic comprehensive tumor profiling service, in facilitating comparisons between tumors that share histological features.

1 Jun 2015

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Today, Pharmacyclics LLC announced the results of the Phase III HELIOS trial (CLL3001), which found that patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who received ibrutinib (IMBRUVICA) in combination with bendamustine and rituximab (BR) experienced an 80% reduction in the risk of progression or death compared to patients receiving placebo in combination with BR.

1 Jun 2015

Study findings underscore importance of PD-1/PD-L1 expression in oncogenic signaling pathways

Caris Life Sciences® today announced the presentation of data from two studies in which researchers utilized Caris Molecular Intelligence®, the company's panomic, comprehensive tumor profiling service, to identify potential therapeutic targets in patients with colorectal and pancreatic cancer subtypes, based on expression of the programmed cell death protein 1 (PD-1) and its ligand, PD-L1.

1 Jun 2015

Researchers identify key driver mutations in glioma samples that confirm tumor heterogeneity

Caris Life Sciences today announced the presentation of data from a study in which researchers identified biomarker changes, including key driver mutations, in 89% of metachronous paired glioma tumors, indicating changes in response to therapy as the disease progresses.

1 Jun 2015

OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

OncoGenex Pharmaceuticals, Inc. announced today that results from a retrospective analysis of the Phase 3 SYNERGY trial showed a benefit with custirsen therapy in men with metastatic castrate-resistant prostate cancer (CRPC) who had a poor prognosis.

1 Jun 2015

ESMO-MCBS: A standard tool to assist oncology clinicians evaluate effective anti-cancer medicines

ESMO, the European Society for Medical Oncology, has announced today the publication of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS), a tool to assist oncology clinicians in evaluating the most effective anti-cancer medicines for their patients.

1 Jun 2015

Nanopatch Jet Coating drug delivery platform wins 2015 Good Design Award

Invetech, a leader in instrument development, custom automation, and contract manufacturing, and Vaxxas, a biotechnology start-up and developer of the Nanopatch™ needle-free drug delivery technology, have been named winners of the 2015 Good Design Award for development of the Nanopatch Jet Coating Instrument, an advanced technology platform to support needle-free dermal drug delivery research and product development. The award was announced last evening at the Good Design Awards Gala Night held in Sydney, Australia.

1 Jun 2015

Epic Sciences presents single cell sequencing data from mCRPC patients at 2015 ASCO

Epic Sciences announced today that the company will present single cell sequencing data, from metastatic castrate resistant prostate cancer patients, at the 2015 annual meeting of the American Society for Clinical Oncology. This application expands the investigational utility of Epic Sciences' no cell left behind™ platform to characterize circulating tumor cell (CTC) genomic alterations.

1 Jun 2015

Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, presented additional preclinical data at the American Association of Cancer Research (AACR) Advances in Brain Cancer Research Conference on the potential for its lead product candidate VAL-083 (dianhydrogalactitol) to treat patients with temozolomide-resistant glioblastoma multiforme (GBM).

1 Jun 2015

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck, known as MSD outside the U.S. and Canada, today announced an expanded collaboration to evaluate the efficacy and safety of talimogene laherparepvec, Amgen's investigational oncolytic immunotherapy, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in a Phase 1, open-label trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).

1 Jun 2015

Research shows HEOR data can be used to better determine value-based reimbursement strategies

Later this week, Cardinal Health Specialty Solutions will present a new series of health economic outcomes research (HEOR) studies that reinforce the importance of evaluating real-world treatment patterns when developing value-based reimbursement strategies.

1 Jun 2015

New clinical studies on Myriad Genetics myChoice HRD companion diagnostic test presented at ASCO 2015

Myriad Genetics, Inc. today announced new clinical studies on its myChoice HRD companion diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in Chicago, Ill.

1 Jun 2015

ClinGen: New clinical genome resource may help understand clinical implications of genetic variants

Tremendous advances have been made in decoding the human genome in recent years but critical questions remain regarding what these variants mean and how they can be applied in clinical practice.

1 Jun 2015

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, and the Congress of the European Hematology Association (EHA), June 11-14.

1 Jun 2015

Pharmacyclics initiates ibrutinib-MEDI4736 combination multi-center study for R/R DLBCL or FL

Pharmacyclics, Inc. today announced the initiation of PCYC-1136-CA, a multi-center study that will investigate the use of ibrutinib (IMBRUVICA®) in combination with MEDI4736, an investigational anti-PD-L1 immune checkpoint inhibitor being developed by AstraZeneca.

1 Jun 2015

Cancer News and Research

Latest Cancer News and Research

New article finds no compelling evidence for withdrawing nitrous oxide from operating theaters

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

PGDx introduces ImmunoSelect-R service to support development of immuno-oncology cancer therapies

Study: Removing more tissue during partial mastectomy could reduce need for second surgery

CHEMOSAT treatment of UM patients with hepatic metastases highlighted at ASCO 2015

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Study findings underscore importance of PD-1/PD-L1 expression in oncogenic signaling pathways

Researchers identify key driver mutations in glioma samples that confirm tumor heterogeneity

OncoGenex's Phase 3 SYNERGY trial shows survival benefits of custirsen therapy in CRPC patients with poor prognosis

ESMO-MCBS: A standard tool to assist oncology clinicians evaluate effective anti-cancer medicines

Nanopatch Jet Coating drug delivery platform wins 2015 Good Design Award

Epic Sciences presents single cell sequencing data from mCRPC patients at 2015 ASCO

Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Research shows HEOR data can be used to better determine value-based reimbursement strategies

New clinical studies on Myriad Genetics myChoice HRD companion diagnostic test presented at ASCO 2015

ClinGen: New clinical genome resource may help understand clinical implications of genetic variants

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Pharmacyclics initiates ibrutinib-MEDI4736 combination multi-center study for R/R DLBCL or FL

Industry Focus eBook - Oncology (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in